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Abstract : Objective— The Shizuoka Stroke Network (SSN) is a stroke prevention system 
that enables general practitioners to manage patients at high risk of stroke with regular 
specialist consultation.  We evaluated blood pressure control, and compared risk of stroke 
among the SSN and three recent cohort studies of patients treated by specialists.
Methods— Blood pressure obtained in 389 patients registered in the SSN were 
retrospectively investigated (at the time of enrollment, and after 1-, 2- and 3-years of follow-
up).  The stroke rate in SSN patients was compared with that in the Japanese Reduction 
of Atherothrombosis for Continued Health (REACH) Registry (n = 5193), Japan Thrombosis 
Registry of Atrial Fibrillation, Coronary and Cerebrovascular Events (J-TRACE) (n = 8,093), 
and Effective Vascular Event Reduction after Stroke Registry (EVEREST) (n = 3,411). 
Results— Systolic and diastolic blood pressure in SSN patients at 1-, 2-, and 3-year follow-up 
were significantly lower (p < 0.001 for each) than at enrollment (135.5, 134.4, 132.2 vs. 146.8 
mmHg ; 76.2, 75.6, 73.6 vs. 81.2 mmHg).  The stroke rate in primary prevention SSN patients 
(0.99 events per 100 person-years, confidence interval； 0.98-1.00) was lower than that in the 
Japanese REACH Registry (1.28-2.07).  The stroke rate in secondary prevention SSN patients 
(3.23, confidence interval； 3.18-3.29) was higher than that in the Japanese REACH Registry 
and J-TRACE (2.95), but lower than that in EVEREST (3.81).
Conclusion— Our stroke prevention system might help general practitioners to manage 
blood pressure and prevent stroke onset as well as specialists.
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Ⅰ．Introduction
　　Stroke causes nearly 10% of all deaths 
worldwide, and is the most common disease 
leading to patients becoming bedridden in 
Japan1,2).  The management of stroke risk factors 
is important for reducing the risk of stroke3,4). 
Although general practitioners play an important 
role in managing these risk factors, certain 
impediments to such management have been 
pointed out, such as inadequate follow-up and 
monitoring, inadequate prescribing of prevention 
therapies, poor information provision, and 
inadequate self-management of risk factors by 
patients5~9).
　　With the aim of providing for a division 
of roles and cooperation through community-
based, critical cooperative paths, the Japanese 
government has promoted a concrete medical 
cooperation system for individual programs 
within medical care plans including stroke, 
cancer, and pediatric emergency medical 
services10).  The cooperation system for stroke 
has been promoted in each community, but 
the promoting of division of roles for stroke 
prevention between general practitioners and 
stroke specialists is not easy in comparison with 
the cooperation system.  Inadequate management 
by practitioners, anxiety of patients and their 
families about leaving the general hospital, and 
lack of a cooperation system between general 
hospital and general practitioners hinder 
promotion of division of roles.  Since late 2006, 
we have managed the Shizuoka Stroke Network 
(SSN), a local stroke network in Shizuoka City 
(population, approximately 720,000)11).  The SSN 
comprises six general hospitals which treat 
88% of all emergency patients in the area, four 
rehabilitation facilities, and approximately 220 
general practitioners.  The SSN consists of two 
connected networks : a network for acute stroke 
(NAS) and a network for stroke prevention (NSP). 
NAS has the aim of rapidly transferring patients 
to a general hospital to receive intravenous 
tissue plasminogen activator or other treatments, 
and to realize the smooth referral of stroke 
patients from general hospitals to rehabilitation 
facilities and general practitioners.  After hospital 
or rehabilitation facility discharge, registration 
in the network shifts from NAS to NSP. NSP 
is concerned with primary and secondary 
prevention of stroke, and is termed a circulating 
referral prevention system.  This system involves 
recurring, scheduled referrals of registered 
patients to general hospitals from general 
practitioners.  The aim of the circulating referral 
prevention system is to maintain highquality 
management of stroke prevention and to provide 
a sense of security to patients and their families.
　　Hypertension is the major risk factor for 
both ischemic and hemorrhagic stroke12,13).  Blood 
pressure (BP) is positively associated with risk 
of stroke14) and reduction of BP diminishes the 
risk of stroke15,16).  Management targets for 
hypertension have been provided by various 
guidelines17～21), but it is not uncommon for BP 
to be refractory to control, and the frequency 
of patients with such uncontrolled BP varies 
among countries8).  The rate of adequate BP 
control is reported at less than 50% for general 
practitioners22), compared with more than 70% 
for specialists23,24).
　　Reductions in stroke recurrence rate 
have been seen in a recent study of Western 
countries25,26) and have also been seen in Japan27
～29).  Recent cohort studies in Japan have 
demonstrated less than 4.0 stroke events per 
100 person-years27～29), about one-third the rate 
found in a previous population-based cohort 
study30).  The patients in these studies were 
recruited from August 2004 to July 2009. 
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Progress in management of risk factors might 
have contributed to this reduction in stroke 
recurrence rate.
　　The purpose of the present study was to 
evaluate the efficacy of the SSN for control 
of BP and for prevention of stroke.  BP was 
the strongest risk factor for any subtype of 
stroke2).  Our hypothesis was that if the rate of 
adequate BP control achieved by the SSN, the 
rate of stroke onset in the SSN would be the 
same as that in patients under the care of stroke 
specialists.  Because our study did not have a 
control group, the rate of stroke in our study 
was compared with that in recent cohort studies 
of patients treated by specialist cardiologists 
and/or neurologists in Japan as a benchmark. 
These studies were the Japanese Reduction of 
Aterothrombosis for Continued Health (REACH) 
Registry27), Japan Thrombosis Registry of Atrial 
Fibrillation, Coronary and Cerebrovascular 
Events(J-TRACE)28), and Effective Vascular Event 
Reduction after Stroke (EVEREST) Registry29).
　　The findings of the present study may 
help to promote the development of prevention 
systems in other regional stroke networks.
Ⅱ．Methods
1．Study design
　　This was a retrospective multicenter cohort 
study.  All subjects were patients registered 
in a network for high-risk patients in the SSN 
involving four general hospitals to which almost 
all stroke patients in this emergency services 
area were transferred.  The registration period 
was between September 2006 and March 2008. 
This study protocol conformed to the ethical 
standards described in the Declaration of 
Helsinki and was approved by an institutional 
review board at each site.
2．Outline of the network for stroke prevention 
(NSP) in the SSN
　　The NSP has primary prevention and 
secondary prevention components.  The aim of 
the primary prevention component is for general 
practitioners to be able to easily consult stroke 
special-ists at a general hospital regarding stroke 
risk for patients with coronary artery disease, 
peripheral artery disease, or multiple risk 
factors for atherothrombosis.  When a general 
practitioner refers a patient to a stroke specialist, 
the stroke specialist evaluates : the history of 
cerebrovascular events ; BP ; current smoking ; 
presence of obesity (body mass index≥25); 
activities of daily living ; pulse wave velocity ; 
ankle-brachial pressure index ; neuroimaging 
findings (usually magnetic reso-nance imaging 
(MRI) and magnetic resonance angiography 
(MRA) ; and risk score.  HbA1c, creatinine, 
triglyceride (TG), low density lipoprotein 
cholesterol (LDL-C), and high density lipoprotein 
cholesterol (HDL-C) were measured as necessary 
in accordance with the patients’ risk factors. 
The stroke specialist evaluates the risk of stroke 
using these data and the clinical examination, 
decides on the schedule for the next consultation, 
and provides feed-back to general practitioners 
on a clinical pathway.  The administration staff 
at the general hospital gives notice of scheduled 
referral to the general practitioner, who then 
make an appointment for their patient to see a 
specialist at the general hospital.  At the next 
consultation, the stroke specialist reevaluates 
the risk of stroke using data from the clinical 
pathways and the clinical examination, and 
provide feedback to the general practitioner 
on new clinical pathway.  In the network for 
secondary prevention, stroke specialists assess 
the risk of stroke and record the data on the 
clinical pathway in the same way as in the 
― 4 ― ― 5 ―
Vol.35　No.1　2015 静岡赤十字病院研究報
network for primary prevention.  This system is 
unique in that stroke specialists can intervene in 
the management of primary prevention, whereas
they do not usually manage risk factors until 
stroke has occurred.
3．Study data and outcome
　　At the time of enrollment, patients were 
assessed for demographic variables, medical 
history, and risk factors using the clinical 
pathways.  BP values were obtained from the 
clinical pathways for the time of enrollment, and 
for 1-, 2-, and 3-year follow-up visits.  Adequate 
BP cont-rol was defined as <140/90 mmHg, and 
rates of adequate BP control were calculated at 
the time of enrolment, and at 1-, 2-, and 3-year 
follow-up visits.
　　Study outcome was all strokes occurring 
during the follow-up period of 3 years.  Stroke 
was diagnosed when a patient had acute onset 
of focal neurological manifestations and the 
responsible lesion was confirmed by brain 
computed tomography or MRI.  To allow 
comparison with other studies, the rate of 
stroke onset was calculated as events per 100 
person-years.  This definition is the same as 
that of J-TRACE and EVEREST.  The REACH 
Registry calculated TIA and stroke separately. 
To compare with the stroke rate of the present 
study and that of previous studies, TIA was not 
recorded.
4．Study supervision
　　This study had a steering committee 
consisting of 7 members and a surveillance 
committee consisting of 4 members.  The steering 
committee members were responsible for the 
study design, study progress management, 
statistical analysis, and preparation for publication. 
The surveillance committee monitored the works 
of the steering committee.
5．Data management
　　We collected all patient data from each 
hospital on recordable compact discs or other 
digital media.  For security purposes, all 
investigators used the same forms, which did not 
include the hospital identification number, name, 
date of birth, or other information that could 
identify patients.
6．Published cohort studies used for comparison
　　The REACH Registry is a large, international, 
prospective cohort of patients with cerebrovascular 
disease (CVD), peripheral artery disease (PAD), 
or mult iple (≥3) r isk factors (MRFs) for 
atherothrombosis27).  In the Japanese REACH 
registry, 5193 patients were enrolled between 
August and December 2004, and l-year follow-
up data were available for 5,021 patients (69.25% 
male, average age 70.31 years).  The number of 
patients with CVD, PAD, and MRFs was 1962, 
603, and 2252, respectively.  The 1-year event rate 
in patients with CVD was compared with that of 
patients with symptomatic atherothrombosis at 
other sites. J-TRACE is a nationwide multicenter 
cooperative cohort of Japanese patients with 
myocardial infraction (MI), stroke, or atrial 
fibrillation (AF).  Baseline characteristics of 8087 
Japanese patients (5804 male, average age 68.7 
years) with a history of stroke (n = 3554), MI (n 
= 2291), or AF (n = 2242) were analyzed28).  The 
manority of referring clinicians were cardiologists 
and neurologists, who referred 58.8% and 27.9% 
of participants, respectively.  The EVEREST 
registry was conducted to investigate 1-year 
rates of atherothrombotic vascular events in 
patients with recent noncardioembolic ischemic 
stroke receiving at least one oral antiplatelet 
agent, and to assess the risk factors for recurrent 
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ischemic stroke in this population29).  At 9-15 
months after enrollment, data on presence/
absence of atherothrombotic vascular events 
were collected.
7．Statistical analysis
　　We used descriptive statistics and reported 
mean and standard deviation (SD) for all mea-
sures.  Changes in systolic and diastolic BP were 
analyzed using one-factor analysis of variance 
(ANOVA) with P < 0.05 indicating statistical 
significance.  If ANOVA showed a significant 
difference, the Bonferroni/Dunn procedure was 
used as a posthoc test.  The event rate was 
expressed as number of events per 100 person-
years.  When multiple events occurred in the 
same patient during the follow-up period, those 
events were regarded as multiple independent 
events.  Statistical analysis was conducted with 
IBM SPSS Statistics 20.0 (IBM-Armonk, NY). 
The 95% confidence interval was calculated 
by the normal approximation for the Poisson 
distribution that the number of events per year 
was assumed to follow.
Ⅲ．Results
　　During this study period, 389 patients 
registered in the network for h igh-r isk 
pat ients were avai lab le for assessment . 
Patient demographic variables are shown in 
Table 1. Primary prevention strategies were 
provided to 131 (34%) patients and secondary 
prevention strategies to 258 (66%) .   For 
the secondary prevention patients, initial 
stroke type was cerebral infarction in 173 
(according to the TOAST classification31), large-
artery atherosclerosis was diagnosed in 38%, 
cardioembolism in 18%, small-artery occlusion 
in 26%, and other determined or undetermined 
etiology in 18%), cerebral hemorrhage in 39, 
subarachnoid hemorrhage in 9, transient ischemic 
attack in 9, and other in 28.  Systolic and diastolic 
BP values at the time of enrollment and at 
the 1-, 2- and 3-year follow-up visits are shown 
in Table 2. SBP and DBP showed significant 
changes (p < 0.001 for each ; one-factor ANOVA), 
and SBP/DBP at 1-, 2-, 3-year follow-up visits 
decreased significantly compared with at the 
Table 1. Baseline characteristics of patients in the 
SSN study
Number of patients 389
Age (years), mean ± SD 71.8 ± 10.5
Men (%) 46
Risk factors for stroke 
　　Hypertension (%) 80
　　Diabetes (%) 22
　　Dyslipidemia (%) 44
　　Atrial fibrillation (%) 12
　　Current smoker (%) 11
　　Obesity (%) 13
SSN= Shizuoka Stroke Network
Table 2. Time course of blood pressu
Enrollment
(n=389)
1-year 
follow-up
(n=257)
2-year 
follow-up
(n=220)
3-year 
follow-up
(n=165)
Blood pressure
SBP (mmHg) 146.8 (22.0) 135.5 (16.0)* 134.4 (14.9)* 132.2 (16.9)*
DBP (mmHg) 81.3 (13.6) 76.7 (10.5)* 75.6 (10.4)* 73.6 (10.6)*
SBP, systolic blood pressure; DBP, diastolic blood pressure; data are means (SD). 
SBP and DBP show significant changes (p < 0.001 for each; one-factor ANOVA), 
and SBP/DBP at 1-, 2-, and 3-year follow-up visits decrease significantly 
compared with at the time of enrolment (by 11.4/4.6, 12.5/5.7, and 14.6/7.7 mmHg, 
respectively; p < 0.001 for each; Bonferroni multiple-comparison test).
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time of enrolment (p < 0.001 for each ; Bonferroni 
multiple-comparison test).  SBP/DBP showed 
no significant differences between primary 
prevention patients and secondary prevention 
patients at the time of enrolment, or at 1-, 2-, 
and 3-year follow-up visits (primary prevention : 
146/79.4, 135.5/75.2, 134.1/73.9, 131.7/71.7 mmHg, 
respectively ; secondary prevention : 147/82.6, 
135.4/77.4, 134.5/76.4, 132.6/74.8 mmHg).  The 
rates of adequate BP control were 40%, 64%, 68%, 
and 76% at the time of enrolment, and at 1-, 2-, 
and 3-year follow-up visits, respectively.
　　During this study period, two primary 
prevention patients and 14 secondary prevention 
patients experienced stroke, and the respective 
rates of stroke in these two patient groups were 
0.99 (confidence interval, 0.98-1.00), and 3.23 (3.18-
3.29) events per 100 person-years.  In comparison 
to the recent published cohort studies, the SSN 
patients were older and less likely to be male 
or current smokers than the J-TRACE and 
EVEREST populations (SSN vs. Japanese REACH 
Registry, J-trace, EVEREST ; mean age, 72 vs. 
70, 69, 69 years old ; male, 46% vs. 69%, 72%, 67% 
; current smokers； 11% vs. 17%, 22%, 23%).  The 
rates of hypertension, diabetes and dyslipidemia 
in the SSN patients were similar to those in the 
other studies.  The rate of stroke in the SSN 
primary prevention patients was lower than that 
in the REACH Registry (Table 3).  The rate of 
stroke in the SSN secondary prevention patients 
was higher than that of subsequent stroke in the 
REACH Registry and J-TRACE, but lower than 
that in EVEREST (Table 3).
Ⅳ．Discussion
　　The rate of adequate BP control at 3-years’ 
follow-up in the SSN patients was 76%, similar 
to rates reported for patients under the care of 
specialists in recent Japanese studies23,24).  As 
mentioned in the results, the rates of stroke onset 
in the SSN patients were also equivalent to those 
in other studies of patients under specialist care. 
These findings might support our hypothesis 
that if the rate of adequate BP control in SSN 
patients could be achieved, the rate of stroke 
Table 3. Comparison of stroke rates between the present study and 
recent cohort studies in Japan
Stroke events per 100 person-years
Primary prevention Secondary prevention
REACH Registry
　Patients with CVD (n = 1962) 2.77
　Patients with CAD (n = 2252) 1.28
　Patients with PAD (n = 603) 2.07
　Patients with MRFs (n = 831) 1.56
J-TRACE (n = 8093) 2.95
EVEREST (n = 3411) 3.81
Present study (n = 389)
　Primary prevention (n = 131) 0.99
　Secondary prevention (n = 258) 3.23
REACH = The REduction of Atherothrombosis for Continued Health; CVD = 
cerebrovascular disease; CAD = coronary artery disease; PAD = peripheral 
artery disease; MRFs = multiple (≥3) risk factors for atherothrombosis other 
than CVD, CAD, and PAD; J-TRACE = Japan Thrombosis Registry of Atrial 
Fibrillation, Coronary and Cerebrovascular Events; EVEREST = Effective 
Vascular Event Reduction after Stroke registry.
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onset in SSN patients would be the same as in 
patients under the care of specialists. 
　　The rate of adequate BP control in the 
present study was only 40% at enrolment, but 
it increased to 64% at the 1-year follow-up visit 
and eventually reached 76% at 3 years.  This 
improvement might result from the circulating 
prevention system, which provided patients 
with regular specialist consultation.  Regular 
evaluation by an external clinician might help 
maintain motivation regarding risk control, not 
only for practitioners but also for patients32).  We 
speculate that the present patients maintained 
their motivation because they could receive 
advice from the specialists and because the 
importance of risk management was reaffirmed 
at follow-up visits.  The low rate of adequate 
BP control at enrolment in the present study 
might be explained as follows.  First, the purpose 
of our network for primary prevention is to 
manage high-risk patients, and many patients 
with uncontrolled BP were enrolled in this study. 
Second, patients who developed stroke were 
usually enrolled at discharge in our network for 
secondary prevention, and many ischemic stroke 
patients were managed with only moderate 
antihypertensive treatment because they were in 
the acute or sub-acute phase.
　　Although the SSN practice of regularly 
performing MRI and MRA might seem excessive, 
it is common practice in Japan.  This might relate 
to the facts that 1）Japan has more MRI units 
per hospital than do other countries33), and 2）
approximately one-quarter of Japanese patients 
with atherosclerotic thrombosis have intracranial 
atherosclerotic stenosis or occlusion34).
　　Some limitations of the present study 
should be considered.  First, we enrolled 
outpatients who could visit practitioners with 
or without assistance, and most patients had 
mild to moderate ischemic stroke.  As a result, 
our study findings are not generalizable to 
patients with severe ischemic stroke.  However, 
as other recent cohort studies have the same 
limitation, comparison of the rate of stroke 
between these studies and the present would be 
reasonable.  Second, adequate BP control was 
defined as <140/90 mmHg in this study, but 
this definition did not consider the difference 
between primary and secondary prevention. 
The guidelines suggest maintaining a normal 
BP, which is defined as 120/80 mmHg or lower 
for primary prevention and 140/90 mmHg 
or lower for secondary prevention)17-21).  The 
benefit of maintaining a normal BP in secondary 
prevention is controversial.  The J-shaped curve 
applies largely to the cardiovascular arterial 
bed rather than the cerebrovascular bed35,36) ; 
however, a recent study demonstrated that 
among patients with recent non-cardioembolic 
ischemic stroke, SBP levels during follow-up in 
the very low-normal (<120 mm Hg) range were 
associated with increased risk of recurrent 
stroke37).  Hence adequate BP control may differ 
among stroke types.  Third, the present cohort 
study started out with fewer males and with 
lesser smokers than the published cohort studies. 
This may have resulted in better stroke rates. 
However.  patients in the SSN were older that 
in published cohort studies.  Aging raises the 
risk of the stroke far more than smoking and sex 
difference2).  We believe that the main results is 
unaffected by the differences in patients’ baseline 
characteristics.
Ⅴ．Conclusions
　　The SSN stroke prevention system might 
have a possibil ity to achieve risk factors 
management and stroke prevention equivalent 
to those achieved by specialists.  We believe that 
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a circulating stroke prevention system can help 
general practitioners to manage risk factors and 
prevent stroke as well as specialists, and promote 
the division of roles for stroke prevention 
between general practitioners and specialists.
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